AA
BPMC

ALPS Advisors’s Blueprint Medicines BPMC Stock Holding History

ALPS Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-39,523
Closed -$1.78M – 1006
2023
Q1 		$1.78M Sell
39,523
-1,034
-3% -$46.6K 0.02% 312
2022
Q4 		$1.78M Buy
+40,557
New +$1.94M 0.02% 315
2022
Q1 		– Sell
-3,677
Closed -$394K – 844
2021
Q4 		$394K Buy
3,677
+44
+1% +$4.6K ﹤0.01% 680
2021
Q3 		$374K Buy
3,633
+356
+11% +$33.2K ﹤0.01% 635
2021
Q2 		$288K Hold
3,277
– – ﹤0.01% 855
2021
Q1 		$319K Buy
+3,277
New +$327K ﹤0.01% 781
2020
Q4 		– Sell
-70,486
Closed -$6.53M – 844
2020
Q3 		$6.53M Sell
70,486
-3,435
-5% -$265K 0.1% 146
2020
Q2 		$5.77M Buy
+73,921
New +$5M 0.08% 146

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

ALPS Advisors's BPMC Position: Q2 2023 in Review

ALPS Advisors sold out of Blueprint Medicines (BPMC) in Q2 2023, closing a stake of 39,523 shares — an estimated $1.78M sold.

ALPS Advisors first reported a position in BPMC in Q2 2020 and held it in 8 quarters. The position peaked at $6.53M in Q3 2020. 222 funds tracked by Wall St. Rank hold BPMC as of Q2 2023.

  • ALPS Advisors reported no remaining Blueprint Medicines position as of Q2 2023 after selling out during the quarter.
  • ALPS Advisors sold 39,523 Blueprint Medicines shares in Q2 2023, an estimated $1.78M.
  • ALPS Advisors first reported a position in Blueprint Medicines in Q2 2020 and held it in 8 quarters.
  • ALPS Advisors's Blueprint Medicines position peaked at $6.53M in Q3 2020.
  • 222 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2023.

Based on ALPS Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.